51.96
-0.57(-1.09%)
Currency In USD
Address
16305–36th Avenue North
Minneapolis, MN 55446
United States of America
Phone
763 392 0767
Website
Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
September 20, 2017
| Name | Title | Pay | Year Born |
| Mr. Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | 838,173 | 1962 |
| Ms. Vicky Hahne CPA | Chief Financial Officer | 413,647 | 1966 |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | 441,277 | 1962 |
| Mr. Brent Eilefson | General Counsel | 0 | N/A |
| Mr. Igor Gorbatchevsky M.D. | Chief Medical Officer | 0 | N/A |
| Mr. Eldon C. Mayer III, M.B.A. | Chief Commercial Officer | 0 | 1961 |
| Ms. Sheri Smith | Acting Head of Clinical Operations | 0 | N/A |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.